Is oral bisphosphonate-related osteonecrosis of the jaw an endemic condition?

Medical Hypotheses

Volumn 78, Issue 2, 2012, Pages 315-318

  Diz, P ^a   Limeres, J ^a   Fedele, S ^b   Seoane, J ^a   Diniz, M ^a   Feijoo, J F ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOCHROME P450 2C8; PROTHROMBIN; VASCULOTROPIN;

ARTICLE; BISPHOSPHONATE RELATED JAW OSTEONECROSIS; ENDEMIC DISEASE; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; JAW OSTEONECROSIS; OSTEOPOROSIS;

AGING; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; GENETIC PREDISPOSITION TO DISEASE; GEOGRAPHY; HUMANS; JAW; JAW DISEASES; RISK FACTORS; WORLD HEALTH;

EID: 84855198908     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.11.011     Document Type: Article

References (30)

1. Russell R.G. Bisphosphonates: from bench to bedside. Ann NY Acad Sci 2006, 1068:367-401.
2. Russell R.G. Bisphosphonates: the first 40 years. Bone 2011, 49(1):2-19.
3. Rodan G.A., Reszka A.A. Bisphosphonate mechanism of action. Curr Mol Med 2002, 2(6):571-577.
4. Russell R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007, 119(Suppl 2):S150-S162.
5. Body J.J. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 2006, 14(5):408-418.
6. American Dental Association Council on Scientific Affairs Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006, 137(8):1144-1150.
7. Ruggiero S.L., Dodson T.B., Assael L.A., Landesberg R., Marx R.E., Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009. J Oral Maxillofac Surg 2009, 67(Suppl 5):2-12.
8. Williamson R.A. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 2010, 39(3):251-255.
9. Khan A.A., Sándor G.K., Dore E., Morrison A.D., Alsahli M., Amin F., et al. Canadian taskforce on Osteonecrosis of the Jaw. bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009, 36(3):478-490.
10. Lo J.C., O'Ryan F.S., Gordon N.P., Yang J., Hui R.L., Martin D., et al. Predicting risk of osteonecrosis of the jaw with oral bisphosphonate exposure (probe) investigators prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010, 68(2):243-253.
11. Sarasquete M.E., González M., San Miguel J.F., García-Sanz R. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 2009, 15(6):382-387.
12. Sarasquete M.E., García-Sanz R., Marín L., Alcoceba M., Chillón M.C., Balanzategui A., et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008, 112(7):2709-2712.
13. Di Martino M.T., Arbitrio M., Guzzi P.H., Leone E., Baudi F., Piro E., et al. A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. Br J Haematol 2011, [Epub ahead of print]. 10.1111/j.1365-2141.2011.08622.x.
14. English B.C., Baum C.E., Adelberg D.E., Sissung T.M., Kluetz P.G., Dahut W.L., et al. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag 2010, 6:579-583.
15. Filleul O., Crompot E., Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010, 136(8):1117-1124.
16. Otto S., Abu-Id M.H., Fedele S., Warnke P.H., Becker S.T., Kolk A., et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence - a multi-centre study. J Craniomaxillofac Surg 2011, 39(4):272-277.
17. Manfredi M., Merigo E., Guidotti R., Meleti M., Vescovi P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg 2011, 40(3):277-284.
18. Favia G., Pilolli G.P., Maiorano E. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol 2009, 36(12):2780-2787.
19. Gasparini G., Saponaro G., Di Nardo F., Moro A., Boniello R., Cervelli D., et al. Clinical experience with spiramycin in bisphosphonate-associated osteonecrosis of the jaw. Int J Immunopathol Pharmacol 2010, 23(2):619-626.
20. Lazarovici T.S., Yahalom R., Taicher S., Elad S., Hardan I., Yarom N. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009, 67(4):850-855.
21. Yarom N., Yahalom R., Shoshani Y., Hamed W., Regev E., Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007, 18(10):1363-1370.
22. Diniz M, López Cedrún JL, Sanromán JF, García A, Feijoo JF, Diz P. Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain. Med Oral Patol Oral Cir Bucal 2011, in press.
23. Barrier A., Lescaille G., Rigolet A., Descroix V., Goudot P., Ruhin B. Jaw osteonecrosis induced by oral biphosphonates: 12 cases. Rev Stomatol Chir Maxillofac 2010, 111(4):196-202.
24. Hong J.W., Nam W., Cha I.H., Chung S.W., Choi H.S., Kim K.M., et al. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos Int 2010, 21(5):847-853.
25. Kwon Y.D., Kim D.Y., Ohe J.Y., Yoo J.Y., Walter C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67(12):2644-2648.
26. Marx R.E., Cillo J.E., Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007, 65(12):2397-2410.
27. Hutchinson M., O'Ryan F., Chavez V., Lathon P.V., Sanchez G., Hatcher D.C., et al. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg 2010, 68(9):2232-2240.
28. Edwards BJ, editor. Merck Pharmaceuticals. Incidence rates of osteonecrosis of the jaw with alendronate. Chicago; 2006.
29. Arduino P.G., Menegatti E., Scoletta M., Battaglio C., Mozzati M., Chiecchio A., et al. Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws. J Oral Pathol Med 2011, [Epub ahead of print]. 10.1111/j.1600-0714.2010.01004.x.
30. Vairaktaris E., Vassiliou S., Avgoustidis D., Stathopoulos P., Toyoshima T., Yapijakis C. Bisphosphonate-induced avascular osteonecrosis of the mandible associated with a common thrombophilic mutation in the prothrombin gene. J Oral Maxillofac Surg 2009, 67(9):2009-2012.